Teva, Mylan Reach Deal Ending MS Drug Litigation In Europe

Law360, New York (November 25, 2013, 2:39 PM EST) -- Mylan Inc. and Teva Pharmaceutical Industries Ltd. announced Monday that they have reached a confidential agreement to settle patent litigation over Teva's multiple sclerosis drug Copaxone in three European courts.

The deal brings to an end the companies' court battles in France, the United Kingdom and the Netherlands, in which Teva sought rulings that Mylan would infringe European Patent Number 0,762,888 with its planned generic version of Copaxone, and Mylan attempted to invalidate the patent.

“Teva Pharmaceutical Industries and Mylan Inc. today announce that certain of their affiliates...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.